4th Circular and Self-Amplifying RNA Therapeutics Summit 2025

With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability, durability, longevity and efficacy for treating a wide array of diseases. This May, the 4th Circular and Self-Amplifying RNA Therapeutics Summit (previously known as 'Next Generation RNA Therapeutics Summit) is landing back in Boston, as the unique opportunity to unite with leading stakeholders in the next generation RNA field, including the likes of Sail Biomedicines, Merck, Novo Nordisk, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs towards the clinic. Join 80+ RNA experts navigating through challenges such as RNA design, delivery, purity and manufacturing to accelerate high-quality and scalable next generation RNA therapeutics and vaccines towards approval and the patients in need.  Speakers: Amit Khandhar, Director of Formulations, HDT Bio, Brian Goodman, Partner, MPM Capital, Chijian Zuo, Vice President, CureMed Biomedical Technology, Christian Kaas, Principal Scientist at Global Nucleic Acid Therapies, Novo Nordisk, Dinesh Chandra, Consultant Scientist, Stealth-Mode Biotech Company, Edo Kon, Director of Business Development, RiboX, Erik Digman Wiklund, Chief Executive Officer, Circio ASA, Fei Lu, Associate Director, CSL Seqirus, Gilles Besin, Chief Scientific Officer, Orbital Therapeutics, Jesse Erasmus, Director - Virology, HDT Bio, Justin Letendre, Scientist, Synthetic Biology, Strand Therapeutics Inc., Michael Mingueneau, Head of Immunology, Sail Biomedicines, Momoko Ishikawa, Senior Scientist, VLP Therapeutics LLC, Nichole Lareau, Associate Principal Scientist, Merck and Co, Prakash Koodathingal, Director of RNA Therapeutic Development, Immunomic Therapeutics, Shigeki Miyake-Stoner, Head of Technology, Replicate Bioscience, William Jia, CSO and Co-founder, Virogin Biotech